New drug may shield celiac patients from gluten damage

NCT ID NCT06001177

Completed Disease control Sponsor: Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called KAN-101 in 55 adults with celiac disease who had been on a gluten-free diet for at least a year. Participants received either KAN-101 or a placebo, then underwent a two-week gluten challenge. The drug appeared to reduce gluten-induced damage to the gut lining compared to placebo. The goal is to see if KAN-101 can help control the disease, not cure it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KAN-101 (a drug given by IV infusion)
What this could lead to: If it works, this could lead to a treatment that helps people with celiac disease tolerate small amounts of gluten without gut damage.
What could go wrong: This is an early Phase 2a trial with only 55 people. The results are promising but need confirmation in larger, longer studies. It may not work for everyone or have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

celiac disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CELIAC DISEASE COELIAC DISEASE

Contacts and locations

Show contact details

Locations

Albert Schweitzer Ziekenhuis, locatie Dordwijk

Dordrecht, South Holland, 3318AT, Netherlands
Alliance for Multispecialty Research, LLC

Wichita, Kansas, 67207, United States
Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
CRST Helsinki Oy

Helsinki, Uusimaa, 00180, Finland
Centre Intégré de Santé et de Services Sociaux-Chaudière Appalaches - Hôtel-Dieu de Lévis

Lévis, Quebec, G6V 3Z1, Canada
Centrum Medyczne Med-Gastr Sp. z o.o.

Lodz, Łódź Voivodeship, 91-034, Poland
Clinical Research Services Turku

Turku, Southwest Finland, 20520, Finland
Connolly Hospital

Dublin, Dublin, D15X40D, Ireland
Diex Recherche Quebec Inc.

Québec, Quebec, G1V 4T3, Canada
Gastromed Sp. z o. o.

Torun, Kuyavian-Pomeranian Voivodeship, 87-100, Poland
Homestead Associates in Research Inc.

Miami, Florida, 33032, United States
Hopital Du Sacre-Coeur De Montreal

Montreal, Quebec, H4J 1C5, Canada
LHSC

London, Ontario, N6A 5W9, Canada
MZ Badania Slowik Zymla Spolka Jawna

Knurów, Silesian Voivodeship, 44-190, Poland
McMaster University

Hamilton, Ontario, L8S 4L8, Canada
Melita Medical

Wroclaw, Lower Silesian Voivodeship, 50-449, Poland
Midland Regional Hospital Mullingar

Mullingar, Westmeath, N91Na43, Ireland
Ochsner Clinic Foundation

New Orleans, Louisiana, 70121, United States
Our Lady of Lourdes Hospital

Drogheda, Louth, A92VW28, Ireland
Peak Gastroenterology Associates

Colorado Springs, Colorado, 80907, United States
Rabin Medical Center

Petah Tikva, Central District, 4941492, Israel
Shaare Zedek Medical Center

Jerusalem, Jerusalem, 9103102, Israel
Sheba Medical Center

Ramat Gan, Central District, 5265601, Israel
Soroka Medical Center

Beersheba, Southern District, 8410101, Israel
Studiengesellschaft BSF Unternehmergesellschaft

Halle, Saxony-Anhalt, 6108, Germany
Tays Research Services

Tampere, Pirkanmaa, 33520, Finland
Unlimited Medical Research Group

Hialeah Gardens, Florida, 33018, United States
WIP Warsaw IBD Point Profesor Kierkuś

Warsaw, Masovian Voivodeship, 00-728, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.